Bookmarks
ID 254: Extension: Impact of Sotrovimab in Treatment of COVID 19
Safe People
Organisation name
Imperial College Health Partners (ICHP)
Applicant name(s)
Funders/ Sponsors
Safe Projects
Project ID
=LEFT(J140,6)
Lay summary
The aims of this study are to generate real-world evidence for the impact of Sotrovimab as well as a number of anti-viral drugs that have been recommended as first, second and third-line therapy for treatment on high-risk Covid-19
Public benefit statement
The aims of this study are to generate real-world evidence for the impact of Sotrovimab as well as a number of anti-viral drugs that have been recommended as first, second and third-line therapy for treatment on high-risk Covid-19 patients with mild to moderate disease, who show no evidence of clinical recovery and compare the outcome with that of patients who did not receive the above recommended medication.
Other approval committees
Latest approval date
15/09/2022
Safe Data
Dataset(s) name
Safe Setting
Access type
TRE